Positioning and Growth Financing of ELIOS Vision in the Glaucoma Market
Positioning and Growth Financing of ELIOS Vision in the Glaucoma Market
Outcome Capital’s expertise in delivering strategic advisory and investment banking services throughout a client’s life cycle and growth is exemplified by our partnership with ELIOS Vision, a pioneering medical technology company developing next generation of glaucoma treatment. Outcome Capital provided ELIOS Vision with strategic support and investment banking expertise since its inception in early 2019 and played a critical role in the company’s growth and success. Over the past several years, Outcome helped position ELIOS Vision as a key innovator in the $2.5 billion glaucoma treatment market, leading to the company’s recent acquisition by global eye health player Bausch + Lomb.
Read the case study:
News
Outcome Capital Launches the First Dedicated Ophthalmology Practice to Address the World’s Leading Cause of Disability
Appoints Paul Ryb Managing Director to Lead Firm’s Expansion BOSTON – July 8, 2025 – Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory […]
Read MoreResources
Outcome Capital Life Science Market Pulse, May 2025
Outcome Capital Life Science Market Pulse May 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
